文献速递乳腺MRUS

乳腺非肿块强化磁共振引导超声成像:转归与恶性肿瘤频率

Magnetic Resonance Imaging-Directed Ultrasound Imaging of Non-Mass Enhancement in the Breast: Outcomes and Frequency of Malignancy.
PubMed 文献 · J Ultrasound Med · 2017-01-21

回顾性分析2005年1月至2011年12月本院5837次乳腺MRI检查,识别918个非肿块强化病灶(879个符合标准),其中331例(38%)推荐靶向超声,284例(86%)接受超声。非肿块强化的超声相关率23%(64/284),有相邻解剖标志者显著更易出现超声相关(P<.001)。全部活检的非肿块强化恶性率18%(55/308),已知原发癌、年龄较大、有解剖标志和病灶较大者恶性更常见(均P<.05),但有(18%)与无(12%)超声相关者恶性率无统计学差异。

要点

  • 非肿块强化伴相邻解剖标志时更易找到超声相关,超声相关率23%(64/284)。
  • 有超声相关者中18%(7/39)活检为恶性,无超声相关者MRI引导活检12%(14/117)为恶性。
  • 已知原发癌、年龄较大、有解剖标志和病灶较大者非肿块强化恶性率更高。

核心结论

  • 非肿块强化伴相邻解剖标志者更易出现超声相关;已知原发癌、年龄较大、有解剖标志和病灶较大者恶性可能性更高;有(18%)与无(12%)超声相关者恶性率无统计学差异,无超声相关不能免除对可疑非肿块强化的活检。

研究设计与样本

  • 回顾性研究,2005年1月至2011年12月本院5837次连续乳腺MRI检查,识别918个建议随访或活检的非肿块强化病灶,879个(96%)符合非肿块强化标准;331例(38%)推荐靶向超声,284例(86%)接受超声评估。

关键影像表现/征象

  • 非肿块强化的超声相关率为23%(64/284)。
  • 相邻解剖标志与超声相关显著相关(P<.001)。
  • 64个超声相关中43个(67%)推荐活检,39个(91%)行超声引导活检,7个(18%)为恶性。
  • 284个病灶中220个(77%)未见超声相关。

诊断标准与关键数值

  • 全部活检的非肿块强化恶性率为18%(55/308)。
  • 有超声相关者恶性率18%(7/39),无超声相关者MRI引导活检恶性率12%(14/117),两者无统计学差异。
  • 恶性率在已知原发癌(P<.001)、年龄较大(P<.001)、有解剖标志(P=.002)和病灶较大(P=.019)时显著更高。

临床应用与阅片要点

  • 对非肿块强化推荐靶向超声时,可关注相邻解剖标志以帮助定位。
  • 已知原发癌、年龄较大、有解剖标志或病灶较大时,非肿块强化恶性可能性更高。
  • 无超声相关不代表良性,可疑非肿块强化仍需活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study was performed to determine the frequency, predictors, and outcomes of ultrasound (US) correlates for non-mass enhancement.

METHODS: From January 2005 to December 2011, a retrospective review of 5837 consecutive breast magnetic resonance imaging examinations at our institution identified 918 non-mass enhancing lesions for which follow-up or biopsy was recommended. Retrospective review of the images identified 879 of 918 lesions (96%) meeting criteria for non-mass enhancement. Patient demographics, pathologic results, and the presence of an adjacent landmark were recorded. Targeted US examinations were recommended for 331 of 879 cases (38%), and 284 of 331 women (86%) underwent US evaluations.

RESULTS: The US correlate rate for non-mass enhancement was 23% (64 of 284). An adjacent landmark was significantly associated with a US correlate (P < .001). Biopsy was recommended for 43 of 64 correlates (67%). Ultrasound-guided biopsy was performed on 39 of 43 (91%); 7 of 39 (18%) were malignant. No correlate was seen for 220 of 284 lesions (77%). At magnetic resonance imaging-guided biopsy, 14 of 117 (12%) were malignancies. For all biopsied non-mass enhancements, the malignancy rate was 18% (55 of 308) and was significantly more prevalent in the setting of a known index cancer (P < .001), older age (P < .001), the presence of a landmark (P = .002), and larger lesion size (P = .019).

CONCLUSIONS: Non-mass enhancement with an adjacent landmark is more likely to have a US correlate compared to non-mass enhancement without an adjacent landmark. Non-mass enhancement in the setting of a known index cancer, older age, a landmark, and larger lesion size is more likely to be malignant. However, no statistical difference was detected in the rate of malignancy between non-mass enhancement with (18%) or without (12%) a correlate. Absence of a correlate does not obviate the need to biopsy suspicious non-mass enhancement.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Newburg AR, Chhor CM, Young Lin LL, et al. Magnetic Resonance Imaging-Directed Ultrasound Imaging of Non-Mass Enhancement in the Breast: Outcomes and Frequency of Malignancy. J Ultrasound Med. 2017. PMID: 28108994. doi:10.7863/ultra.16.03001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。